Exome Asset Management »

Nextcure shares owned by Exome Asset Management

Quarter-by-quarter ownership of Nextcure (NXTC) shares owned by Exome Asset Management from 13F filings

Historical chart of Exome Asset Management investment in Nextcure

Tip: Access up to 7 years of quarterly data

All positions including Nextcure held by Exome Asset Management consolidated in one spreadsheet with up to 7 years of data

Download as csvDownload consolidated filings csv Download as ExcelDownload consolidated filings xlsx

Quarterly reported holdings in Nextcure by Exome Asset Management

Quarter filed Position value Share count Share price at filing
2025-12-31 $2.3M 165k 14.19

More positions owned by Exome Asset Management

Praxis Precision Medicines I Com New (PRAX)
Cogent Biosciences (COGT)
Guardant Health (GH)
Ionis Pharmaceuticals (IONS)
Eli Lilly & Co. (LLY)
Cytokinetics Com New (CYTK)
Wave Life Sciences SHS (WVE)
Vera Therapeutics Cl A (VERA)
Bridgebio Pharma (BBIO)
Anthem (ELV)
Astrazeneca Sponsored Adr
Jazz Pharmaceuticals Shs Usd (JAZZ)
Natera (NTRA)
Immunovant (IMVT)
Universal Hlth Svcs CL B (UHS)

View all positions for Exome Asset Management

Top funds holding Nextcure

Affinity Asset Advisors
Ikarian Capital
Sofinnova Ventures
Silverarc Capital Management
Exome Asset Management
Pfizer
AWM Investment Company
Vanguard Group
Boothbay Fund Management
Renaissance Technologies
BlackRock
Acadian Asset Management
Geode Capital Management
Cardiff Park Advisors
Marshall Wace

View all funds holding Nextcure